Floatz logo

NPLD

HER2-negative Metastatic Breast Cancer

Prof. Wolfgang JanniPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the HER2-negative Metastatic Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
Prof. Wolfgang Janni
Phase 3B

Same molecule, other indications

NPLD is also rated in:

breast cancerDormant
CCC
Indicative ·
48 / 100
View asset →
HER2-positive Circulating Tumor CellsDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →